Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy

Cancer statistics for the year 2020: An overview

(2021) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review

(2021) Lai Heng Lee et al.   Frontiers in Cardiovascular Medicine

Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

(2020) Josep Garcia et al.   CANCER TREATMENT REVIEWS

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

(2020) Nadia Howlader et al.   NEW ENGLAND JOURNAL OF MEDICINE

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

(2019) Nigel S. Key et al.   JOURNAL OF CLINICAL ONCOLOGY

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma

(2018) Li-Juan Li et al.   Journal of Thoracic Disease

Angiogenesis Inhibitors in NSCLC

(2017) Anna Manzo et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan

(2015) Kuo-Hsuan Hsu et al.   PLoS One

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

(2014) Jai N. Patel et al.   CANCER

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

(2014) Robert C. Doebele et al.   CANCER

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Epidemiology and Pathophysiology of Nephrotic Syndrome-Associated Thromboembolic Disease

(2012) B. A. Kerlin et al.   Clinical Journal of the American Society of Nephrology

Epidemiology and pathophysiology of cancer-associated thrombosis

(2010) S Noble et al.   BRITISH JOURNAL OF CANCER

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Outcome of Patients With Upper-Extremity Deep Vein Thrombosis

(2007) Francisco José Muñoz et al.   CHEST